The effect of CT26 tumor-derived TGF-β on the balance of tumor growth and immunity

Abstract

Introduction TGF-β is an important target for many cancer therapies under development. In addition to suppressing anti-tumor immunity, it has pleiotropic direct pro- and anti-tumor effects. The actions of increased endogenous TGF-β production remain unclear, and may affect the outcomes of anti-TGF-β cancer therapy. We hypothesize that tumor-derived TGF-β (td-TGF-β) plays an important role in maintaining tumor remission by controlling tumor proliferation in vivo, and that decreasing td-TGF-β in the tumor microenvironment will result in tumor progression. The aim of this study was to examine the effect of TGF-β in the tumor microenvironment on the balance between its anti-proliferative and immunosuppressive effects. Methods A murine BALB/c spontaneous colon adenocarcinoma cell line (CT26) was genetically engineered to produce increased active TGF-β (CT26-TGF-β), a dominant-negative soluble TGF-β receptor (CT26-TGF-β-R), or the empty neomycin cassette as control (CT26-neo). In vitro proliferation rates were measured. For in vivo studies, the three cell lines were injected into syngeneic BALB/c mice, and tumor growth was measured over time. Immunodeficient BALB/c nude mice were used to investigate the role of T and B cells. Results In vitro, CT26-TGF-β-R and CT26-TGF-β cells showed increased and suppressed proliferation, respectively, compared to control (CT26-neo), confirming TGF-β has direct anti-tumor effects. In vivo, we found that CT26-TGF-β-R cells displayed slower growth compared to control, likely secondary to reduced suppression of anti-tumor immunity, as this effect was ablated in immunodeficient BALB/c nude mice. However, CT26-TGF-β cells (excess TGF-β) exhibited rapid early growth compared to control, but later failed to progress. The same pattern was shown in immunodeficient BALB/c nude mice, suggesting the effect on tumor growth is direct, with minimal immune system involvement. There was minimal effect on systemic antitumor immunity as determined by peripheral antigen-specific splenocyte type 1 cytokine production and tumor growth rate of CT26-neo on the contralateral flank of the same mice. Conclusion Although TGF-β has opposing effects on tumor growth, this study showed that excessive td-TGF-β in the tumor microenvironment renders the tumor non-proliferative. Depleting excess td-TGF-β may release this endogenous tumor suppressive mechanism, thus triggering the progression of the tumor. Therefore, our findings support cautions against using anti-TGF-β strategies in treating cancer, as this may tip the balance of anti-immunity vs. anti-tumor effects of TGF-β, leading to tumor progression instead of remission.

The inhibitory effects of probiotics on colon cancer cells: in vitro and in vivo studies

“…At day 21, the mice were sacrificed by cervical dislocation. Tumor volume was measured using a digital vernier caliper and calculated using the following formula: V=1/2L×W 2 , where L = length, and W = width (10).…”

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?

“…Some experimental data on mice preclinical models of pMMR colon cancer summarize this phenomenon. Transforming growth factor–β (TGFβ), an immunosuppressive cytokine associated with bad prognosis, was observed in the tumor bed of preclinical models of colon cancer (20, 21). TGFβ acts on the fibroblastic stroma, increases fibrosis and limits tumor core T cell invasion.…”

How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes

“…Its increased expression in primary colon tumor specimens correlated with metastatic disease and poor prognosis. It should nevertheless be mentioned, at this point, that the direct interplay between TGFβ and colon cancer cells can obviously mediate both tumor-promoting and tumor growth-arresting effects depending on the stage and type of disease, emphasizing the complexity of its involvement in the pathogenesis of CRC [ 132 , 133 ]. However, focusing on its impact on the immune system-mediated control of colon cancer and CRC metastasis, TGFβ has been definitively identified as a driver of tumor immune escape mechanisms, and its targeted inhibition in different preclinical in vivo models successfully dampened the development and metastasis of colon cancer and increased the efficacy of adoptive NK cell therapy [ 131 , 134 ].…”